Back to search

Article

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

2022-11-15

Abstract excerpt

Introduction Lenalidomide maintenance after autologous stem cell transplant (ASCT) is standard of care for myeloma (MM) patients, based on trials in which lenalidomide was planned to continue until disease progression. As outcomes for myeloma patients continue to improve, understanding whether time limited maintenance is as effective as treatment to progression is a critical question. Optimal duration may differ i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
11288219-a01f-5f3a-87fe-946f3982d0de
DOI
10.1182/blood-2022-165376
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI TrialDOI 10.1182/blood-2022-165376
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity
Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneSemantic proximity
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.Semantic proximity
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patientsSemantic proximity
Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationSemantic proximity
Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.Semantic proximity
Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India – Knowing the UnknownSemantic proximity
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity
Select a neighboring publication to make it the new centre.